New drugs for Alzheimer's disease

On October 26, the 11th clinical trial conference of Alzheimer's disease was held in Barcelona, Spain from 24 to 27 Chinese scientists first introduced a new Chinese drug, mannan oligosaccharide diacid (gv-971), which can significantly improve the cognitive impairment of Alzheimer's disease patients and attract international attention Alzheimer's disease is a neurodegenerative disease Its symptoms include memory impairment, aphasia, personality and behavior changes The cause of the disease is still unknown, so there is no effective treatment drug According to reports, the clinical phase 3 trial of the drug was led by Xiao Shifu, Shanghai Mental Health Center, Zhang Zhenxin, Beijing Union Medical College Hospital, and Geng Meiyu, the main inventor of gv-971, Shanghai Institute of medicine, Chinese Academy of Sciences, with the participation of researchers from 34 clinical trial sites in China The results showed that gv-971 had good safety and tolerance in the improvement of cognitive function "Gv-971 is an ocean derived oligosaccharide drug, which can play its role in anti Alzheimer's disease by inhibiting the aggregation of β - amyloid protein, regulating the imbalance of intestinal flora, reducing neuroinflammation and other multi-target characteristics," Geng said at the meeting "This research result is the closest to a successful anti Alzheimer's drug in more than 10 years since cholinesterase inhibitors have been on the market," Rachel Schindler, member of the Scientific Committee of the 11th Alzheimer's clinical trial conference, said at the meeting Professor Eric Lehman, executive director of the banner Institute of Alzheimer's disease, said: "gv-971, with its unique mechanism and encouraging cognitive function improvement ability, is expected to provide multiple treatment options for patients with Alzheimer's disease It is expected to carry out more clinical studies on the drug and further verify its multi-target mechanism in clinical patients " Jeffrey Cummings, a professor of Cleveland Clinic in the United States, said: "gv-971 can improve the cognitive function of patients in a sustainable and stable way, providing a new program for the treatment of Alzheimer's disease We look forward to conducting clinical trials of gv-971 in many places around the world in the future to benefit patients all over the world as soon as possible " Shanghai Green Valley Pharmaceutical Co., Ltd., which participated in the research and development, has submitted a new drug listing application in China on October 16, and plans to conduct global clinical trials in the future Lu Songtao, chairman and general manager of Lvgu pharmaceutical, said that they expected to work with global partners to continue to fight against Alzheimer's disease.